Nanomedicine · 2017 · 39 citations · 25 references
PharmacyOncologyPharmacologyChemotherapyDrug DeliveryNanoparticle Drug DeliveryCancer Drug DeliveryCancer NanomedicineDrug EncapsulationNanocarriers For TherapeuticsNanomedicineNanoparticle FormulationsBreast Cancer ChemotherapyCancer NanotherapyDrug Delivery NanocarriersNanocarrier BiocompatibilityNanocarrier-based ProdrugsNanoemulsion SystemsNanoparticle-based ChemotherapyNanoparticle-delivered Prodrugs
AIM: To develop an acid-sensitive lipidated, doxorubicin (Dox) prodrug (C16-Dox) to be entrapped in lipid nanoemulsion (NE-C16-Dox) as a nanocarrier to treat breast cancer models (in vitro and in vivo). RESULTS: We report the efficacy of NE-C16-Dox in in vitro experiments, as well as the improved chemotherapeutic index and tumor-control efficacy compared with treatment with free Dox in an in vivo murine 4T1 breast cancer model. In addition, NE-C16-Dox allowed the use of a higher dose of Dox, acceptable biocompatibility and a significant reduction in lung metastasis. CONCLUSION: Taken together, these results indicate that NE-C16-Dox is promising for breast cancer treatment, thus creating possibilities to translate these nanotechnology concepts to clinical applications.
25
E O’Brien, Nely Wigler, Moshe Inbar et al. · Annals of Oncology · 2004 · 1.7K citations · Full text
Medicine, Oncology, Pharmacology +17
C. Marcela Díaz‐Montero, Mohamed L. Salem, Michael I. Nishimura et al. · Cancer Immunology Immunotherapy · 2008 · 1.2K citations
Medicine, Cancer Biology, Oncology +17